Document:

exv10w01

 

Exhibit 10.01

SILICON IMAGE, INC.

DIRECTOR COMPENSATION PLAN

     This compensation plan for members of the Board of Directors (the “Board”) of Silicon Image,
Inc. (the “Company”) is effective beginning April 5, 2005 and replaces the director compensation
structure previously in effect.

     Initial Stock Option Grant. Upon appointment or election to the Board, each non-employee
director will receive an option to purchase 40,000 shares of the Company’s common stock under the
Company’s 1999 Equity Incentive Plan (the “1999 EIP”). Such option will have an exercise price
equal to the fair market value of the Company’s common stock on the date of grant. So long as the
director continues to provide services to the Company, this initial stock option grant will vest
and become exercisable with respect to 2.083% of the shares each month following the date of grant
until fully vested; provided, that all shares subject to the stock option will become fully vested
if the Company undergoes a change of control. These initial stock option grants will have a
ten-year term, but will generally terminate three months following the date the director ceases to
perform services for the Company.

     Annual Compensation by Role and for Meeting Attendance.

	 	•  	Cash Compensation by Role. Each non-employee director will receive cash
compensation for membership on the Board, the standing committees and for holding
chair positions on the Board and the standing committees in the amounts and on the
terms described in the table and note (a) below.
	 
	 	•  	Cash Compensation for Meeting Attendance. Each non-employee director will
receive cash compensation for attendance at certain Board and Board committee
meetings in the amounts and on the terms described in the table and notes (c) and
(d) below.
	 
	 	•  	Annual Stock Option Grant(s). Immediately following each annual meeting of
stockholders, each director who is not an employee and whose direct pecuniary
interest in the Company’s common stock is less than five percent will receive stock
option grant(s) under the 1999 EIP in the amounts and on the terms described in the
table and note (b) below, provided such director has served in the role indicated
continuously for a period of at least one year. The shares subject to the annual
stock option grants will have an exercise price equal to the fair market value of
the Company’s common stock on the date of grant. So long as the director continues
to provide services to the Company, these annual grants will vest with respect to
4.167% of the shares each month following the date of grant until fully vested;
provided, that these grants will become fully vested if the Company undergoes a
change of control. These annual stock option grants will have a five-year term, but
will generally terminate three months following the date the option holder ceases
to provide services to the Company.

 

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	Annual Cash	 	 	 	Annual Stock	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	Retainer	 	 	 	Option Grant	 	 	 	 	 	 	 	 	Telephone	 	 
	 	Role	 	 	by Role (a)	 	 	 	by Role (b)	 	 	 	Meeting Fees	 	 	 	Meeting Fees	 	 
	 	Board Member
	 	 	$	25,000	 	 	 	20,000 shares	 	 	$1,000/meeting (c)	 	 	$500/meeting (c)	 
	 	Board Chair
	 	 	$	10,000	 	 	 	5,000 shares	 	 	 	 	 	 	 	 	 	 	 
	 	Audit Committee Member
	 	 	$	10,000	 	 	 	5,000 shares	 	 	$1,000/meeting (d)	 	 	$500/meeting (d)	 
	 	Audit Committee Chair
	 	 	$	10,000	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	Compensation
Committee Member
	 	 	$	5,000	 	 	 	5,000 shares	 	 	$1,000/meeting (d)	 	 	$500/meeting (d)	 
	 	Compensation
Committee Chair
	 	 	$	7,000	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	Governance and
Nominating Committee
Member
	 	 	$	5,000	 	 	 	5,000 shares	 	 	$1,000/meeting (d)	 	 	$500/meeting (d)	 
	 	Governance and
Nominating Committee
Chair
	 	 	$	7,000	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 

	 	(a)  	These cash amounts are additive with respect to each role performed by the
applicable director. For example, if a director serves on the Board, as chair
of the Audit Committee and member of the Compensation Committee, he will
receive an annual cash retainer in the amount of $50,000 ($25,000 as Board
member, $10,000 as Audit Committee member, $10,000 as chair of the Audit
Committee and $5,000 as Compensation Committee member).
	 
	 	(b)  	These option amounts are additive with respect to each role
performed by the applicable director. For example, if a director has served
continuously for a period of at least one year on the Board, as chair of the
Audit Committee and member of the Compensation Committee, he will receive one
or more stock options to purchase an aggregate of 30,000 shares of the
Company’s common stock (20,000 shares as Board member, 5,000 shares as Audit
Committee member and 5,000 shares as Compensation Committee member). A
director must serve in a role continuously for a period of at least one year to
receive the option grant for the respective role.
	 
	 	(c)  	These cash amounts are payable to a director with respect to
all meetings after the sixth meeting of the Board that the applicable director
attended, either in person or via telephone.
	 
	 	(d)  	These cash amounts are payable to a director with respect to
all committee meetings that the applicable director attended, either in person
or via telephone.exv10w02

 

Exhibit 10.02

April 22, 2005

Dale Brown

Dear Dale,

I am pleased to award you a bonus in the gross amount of $27,750.00, less deductions for taxes and
withholding. You will receive this amount with your paycheck dated April 30, 2005. This award will
be subject to the terms and conditions described on Attachment 1.

Thank you for your hard work, dedication, and loyalty to the Company. You have worked through a
challenging environment and I want you to know I really appreciate your efforts and contributions.
I also look forward to continuing to work with you in the future.

As this is a very special award, not related to your 2005 management bonus target. Please do not
discuss with anybody in the Company except for Bob Gargus, Darrel Slack, HR, or me.

Congratulations and keep up the great work!

Sincerely,

/s/ Steve Tirado

Steve Tirado

Chief Executive Officer

 

 

Dale Brown Bonus Dated April 30, 2005

Terms & Conditions

Attachment 1

If your employment is involuntarily terminated for Cause or voluntarily terminated without
Good Reason, you will be required to pay back to the company a pro-rata portion of the bonus. The
amount due to the company will be reduced by 8.333% after the first one (1) month of employment
beginning with the award date, and thereafter, at 8.333% after each full succeeding month you are
employed by the Company.

“Good Reason” shall mean, without your express prior written consent, the occurrence of any one or
more of the following: (a) a material reduction or material adverse alteration in your position,
title, duties, or responsibilities from those in effect as of the award date, or (b) a reduction by
the Company of your base salary or target annual bonus percentage in effect on the award date,
unless said reduction is part of a uniform reduction applied to all similarly situated employees.

“Cause” shall mean (i) any breach of this agreement, the Employee Inventions and Confidentiality
Agreement between you and the Company, or any other written agreement between you and the Company,
if such breach causes harm to the Company; (ii) any negligence or willful misconduct by you in your
performance of duties to the Company that causes harm to the Company, including (without
limitation) repeated failure to follow the directions of the person to whom you report; (iii) your
repeated failure to diligently follow the lawful directions of the Board of Directors of the
Company or your repeated failure to diligently perform your duties in a reasonable manner pursuant
to this agreement; (iv) your commission of a felony under the laws of the United States or any
state thereof; (v) your commission of any act of fraud, embezzlement or dishonesty or breach of
fiduciary duties; (vi) your abuse of alcohol or controlled substances that has a detrimental effect
upon your performance of your duties under this agreement; or (vii) a good faith determination by
the Company’s Board of Directors or the person to whom you report that you have failed to perform
your material duties to the Company after written notice and a reasonable opportunity to cure. A
termination without Cause shall mean a termination for any reason other than those listed in
clauses (i)-(vii) of the preceding sentence or death or disability.

Agreed and accepted,

	 	 	 	 	 	 	 
	/s/ Dale Brown

	 	4/22/2005
	 	/s/ Steve Tirado
	 	4/22/2005
	 	 	 
	Dale Brown

	 	Date
	 	Steve Tirado
	 	Dateexv10w36

 

EXHIBIT 10.36

[Spectranetics letterhead]

February 14, 2005

Cardiovascular Institute of the South

2730 Ambassador Caffery Parkway

P.O. Box 61160

Lafayette, LA 70596-1160

Dear Craig and David:

I am writing to follow up on the conversations that we have had on number of occasions over the
past several months regarding the Peripheral Vascular Training “Gloves On” courses that you operate
through the Cardiovascular Institute of the South. I appreciate the opportunity you have afforded
Spectranetics to interface with cardiologists, vascular surgeons and radiologists during these
courses through a secondary sponsorship. I certainly believe that providing the exposure to the
laser during these peripheral training courses adds value to Spectranetics. Your ability to
showcase the proper applications for the laser in the treatment of both peripheral vascular
disease, in particular critical limb ischemia, as well as, coronary artery disease is very
impactful.

We have followed up with a number of physicians who have participated in these “Gloves On” courses
during 2004. We have testimonials of the effectiveness of our technology. Many of these
physicians return to their hospitals and begin practicing laser atherectomy or request a laser to
initiate this program. We appreciate the opportunity to follow up immediately with the
participants of your course to help them establish a laser program. We try to “strike while the
iron hot”.

In keeping with my commitment to renew on our agreement on training, I would like to extend to you
our interest in continuing to train physicians through “Gloves On” courses. I understand that you
will have approximately 70 courses in 2005. We would like to continue the training provided
directly by both of you in each of these scheduled courses. We would also like to consider
scheduling a dedicated Spectranetics customer course for this fall, for several leading
interventionalists and vascular surgeons, to learn the special techniques and protocols that you
teach.

Spectranetics will continue to be a major participant at the New Cardiovascular Horizon course in
New Orleans. We would also like to continue having you both present at programs around the country
such as teaching hospital grand rounds, etc. We will also hope that you will continue to develop
white papers, peer reviewed abstracts and journal articles based on your outstanding work with the
excimer laser.

 

 

Cardiovascular Institute of the South

February 14, 2005

Page 2

I also recognize that there is an appropriate compensation that should be in place to keep
Spectranetics active in the “Gloves On” program. I have discussed this with you in light of our
past agreements, within the confines of our budgets and in the environment of new regulatory
guidance provided by the AdvaMed code of ethics and the Sarbanes-Oxley legislation.

In keeping with all of our interests, we would therefore like to extend our financial agreement for
the training of the attendees of the “Gloves On” courses scheduled for 2005. We have budgeted
$75,000 for each of you for the year of 2005. This represents $18,750 per quarter.

We recognize this represents a significant opportunity for us to work together to appropriately
train our customers. It is the single largest investment that we make in our training and a very
large percentage of our total training investment. We look forward to working with you and ask
that you individually confirm your agreement to this offer in the signatory space below. If you
have any questions, please do not hesitate to contact me. I look forward to our most productive
year ever together.

With warm regards,

/s/ John Schulte

John Schulte

	 	 	 
	   /s/ David Allie, MD

	 	   /s/ Craig Walker, MD
	 

	 	 
	Dr. David Allie

	 	Dr. Craig Walker

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00084-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00084-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00084-of-00352.parquet"}]]